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Abstract
While sample sizes in randomized clinical trials are large enough to estimate the aver-
age treatment effect well, they are often insufficient for estimation of treatment-covariate
interactions critical to studying data-driven precision medicine. Observational data from
real world practice may play an important role in alleviating this problem. One common
approach in trials is to predict the outcome of interest with separate regression models in
each treatment arm, and recommend interventions based on the contrast of the predicted
outcomes. Unfortunately, this simple approach may induce spurious treatment-covariate
interaction in observational studies when the regression model is misspecified. Motivated
by the need of modeling the number of relapses in multiple sclerosis patients, where the
ratio of relapse rates is a natural choice of the treatment effect, we propose to estimate
the conditional average treatment effect (CATE) as the relative ratio of the potential out-
comes, and derive a doubly robust estimator of this CATE in a semiparametric model of
treatment-covariate interactions. We also provide a validation procedure to check the qual-
ity of the estimator on an independent sample. We conduct simulations to demonstrate
the finite sample performance of the proposed methods, and illustrate the advantage of
this approach on real data examining the treatment effect of dimethyl fumarate compared
to teriflunomide in multiple sclerosis patients.
1 Introduction
Recently, interest in recommending tailored preventative interventions or treatments to pa-
tients in clinical practice has prompted investigating conditional average treatment effects
(CATE) from data. Knowledge of CATE as the contrast between the expected outcome for
different interventions conditional on different covariate levels would allow clinicians to iden-
tify whether a patient would benefit from a particular intervention based on their covariates.
The primary statistical objective is to estimate these CATE by examining treatment-covariate
interactions [23]. In this work, we study the estimation and validation of a special type of
CATEs using observational data.
The estimation of the difference in expectations of potential outcomes as the CATE, i.e.,
EpY p1q´Y p0q | Z “ zq, using observational data has been studied extensively in the literature
[12, 28, 18, 17, 26, 2, 15]. Recently, [19] and [27] compare a number of approaches for learning
this function. The basic idea is either estimating the CATE based on separately estimated
EpY prq | Z “ zq, r “ 0, 1, or learning CATE directly based on modified outcomes. However,
in some settings, the absolute difference in potential outcomes is not the best measure of
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treatment effect. For example, if the ratio
Dpzq “ ErY
p1q|Z “ zs
ErY p0q|Z “ zs
is constant for all z, but ErY p0q|Z “ zs varies with z, then there will appear to be significant
treatment effect heterogeneity measured by the absolute difference ErY p1q ´ Y p0q|Z “ zs,
which may not be of particular interest. In this work, we focus on estimating the ratio of the
conditional expectation of the potential outcomes given the baseline covariates, rather than
the difference thereof, motivated by the study of relapse in multiple sclerosis (MS) patients.
We also provide a general framework for the estimation and validation of such a CATE score.
The outcome weighted learning (OWL) is another class of methods for developing precision
medicine [31, 32, 7, 33]. OWL methods find a decision boundary in the covariate space to
classify patients into those with a treatment benefit tz | Dpzq ă 1u or harm tz | Dpzq ą 1u,
if Y represents undesirable events. The OWL method and its variations convert the original
task into a binary classification problem and directly target the decision boundary, bypassing
the need to estimate the CATE [29]. In contrast, the regression approach above attempts
to directly estimate the magnitude of the benefit via the CATE, and then identify the high
value subgroup of patients accordingly [6, 10, 30]. The OWL approach avoids the more
difficult task of estimating treatment effect for each patient, but also fails to yield information
about the size of the treatment benefit for individual patients that may be important in cost-
effectiveness analyses, which seek to balance the economic cost and risk of adverse events with
treatment benefits. A good estimator of the CATE ensures a good average treatment effect
(ATE) within the subgroup consisting of patients with the largest CATEs, thus assigning
priority of receiving the treatment in the population. In the spirit of precision medicine,
we may also directly recommend the treatment to individual patients whose estimated CATE
outweighs the associated cost, which may also be patient-dependent. Therefore, in this paper,
we focus on the more general question of directly estimating the CATE rather than a binary
recommendation rule.
1.1 A motivating example
The NeuroTransData (NTD) multiple sclerosis (MS) registry includes about 25,000 patients
with multiple sclerosis, which represents about 15% of all MS patients in Germany. It includes
demographic, clinical history, patient related outcomes and clinical variables captured in real
time during clinical visits. The data contain few missing values, thanks to processes to manage
the definition of minimum data sets, mandatory data entry fields, and positive missing data
confirmation. Dynamic web-based data capturing, regular training of doctors and nurses,
interactive chat forum for nurses and doctors, automated and manual feedback query system,
daily automated analysis of data plausibility and correctness and annually on-site audit of
procedures and source data by an external process quality certifier organization ensure the
data is accuracy.
All data are pseudonymized and pooled to form the MS registry database. The codes are
managed by the Institute for medical information processing, biometry and epidemiology (In-
stitut fr medizinische Informationsverarbeitung, Biometrie und Epidemiologie) at the Ludwig
Maximilian University in Munich, Germany, acting as an external trust center. This data
acquisition and management protocol was approved by the ethical committee of the Bavarian
Medical Board (Bayerische Landesrztekammer; June 14, 2012) and re-approved by the ethi-
cal committee of the Medical Board North-Rhine. (rztekammer Nordrhein, April 25, 2017).
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Compliance with European and German legislation is warranted including patient rights and
informed consent requirements.
For this project, data were extracted from two groups of patients with relapsing remit-
ting multiple sclerosis captured between Jan/1/2009 and July/1/2018, who received either
Dimethyl fumarate (DMF, n “ 1741) or Teriflunomide (TERI, n “ 1050), respectively. The
focus of the analysis is to estimate the CATE of TERI compared with DMF and stratify
the patient population for tailored treatment recommendation. The outcome of the primary
interest is the number of relapses per unit time; the average treatment effect is measured by
the ratio of the expected relapse rate under TERI versus that under DMF.
Three questions arise when trying to analyze CATEs in the NTD registry:
1. Can we use the ratio rather than the difference in expected outcomes to measure the
treatment effect?
2. How do we adjust for differences in baseline covariates (confounders) between two treat-
ment groups, and how do these affect estimation of the CATE?
3. How do we validate our CATE model based on observational data and will the resulting
method provide a useful measure of the quality of the estimated CATE score?
The remainder of the introduction serves to detail the nuances of these questions, and the
following sections discuss our approach to answer them.
1.2 The relapse rates ratio as the measure of CATE
The standard regression model for the number of relapses in terms of the baseline covariates
is the Poisson or Negative Binomial regression by treatment arm:
EpY prq|F prq, Z,R “ rq “ exppβJr rZqF prq, r “ 0, 1, (1)
where rZ “ p1, ZJqJ is a d` 1 dimensional covariate vector, R is the binary indicator of the
treatment received, and pY prq, F prqq are the potential number of relapses and exposure time,
when the patient receives the treatment r P t0, 1u. Our goal is to model the effect of the
treatment on the relapse rate. Under this regression model, the expected number of relapses
per unit time for a group of patients with the same covariate Z “ z under treatment r, is
E
˜
Y prq
F prq
ˇˇˇˇ
Z “ z
¸
“ exppβJr rzq,
where rz “ p1, zJqJ. With the estimated regression coefficients pβ0 and pβ1, let
pµrpzq “ exptpβJr rzu
be an estimator of the relapse rate under treatment r P t0, 1u. Noting that the ratio of the
expected relapse rates
Dpzq “ EpY
p1q{F p1q|Z “ zq
EpY p0q{F p0q|Z “ zq (2)
is a natural measure of the CATE for the relapse rate that is insensitive to differences in
exposure time between patients, a simple estimate of the CATE is
pDpzq “ pµ1pzqpµ0pzq “ exptppβ1 ´ pβ0qJrzu, (3)
3
under model (1.2).
We only observe pY prq, F prqq, when R “ r, leading to a causal-missing data problem. We
consider the following generalization of the unconfoundedness assumption [13] that identifies
the relapse rate:
tY p1q, F p1q, Y p0q, F p0qu K R | Z. (4)
This implies that EpY | F,Z,R “ rq “ EpY prq | F prq, Z,R “ rq “ EpY prq | F prq, Zq. Note that
if the exposure times F prq ě F ą 0, all analyses only depend on Y prq{F prq. And so, in the
rest of the paper, we assume that F prq “ 1, without loss of generality. Consequently, Dpzq
reduces to EpY p1q | Z “ zq{EpY p0q | Z “ zq.
1.3 Confounding effect on estimating CATE
If the regression models for Y given Z and the treatment assignment R are correctly specified,
then the current regression method doesn’t need to be altered in an observational study sincepβr is expected to converge to the true regression coefficient as the sample size increases.
In practice, these statistical models may be mis-specified and only serve as working models
approximating the true relationship between outcomes and covariates. In such a case, the
estimated regression coefficients may converge to limits that introduce spurious predicted
treatment heterogeneity.
The following toy example illustrates this phenomenon. Assume that Y | Z “ z follows
a Poisson distribution with a rate of z2 in both arms, i.e., there is no treatment effect for
any Z “ z. To mimic the confounding effect in an observational study, we assume that
Z | R “ 1 „ Np0.5, 1q, and Z | R “ 0 „ Np´0.5, 1q. If we fit a misspecified Poisson regression
model
EpY |Z “ z,R “ rq “ exppβJr rzq
in two arms separately, the regression coefficient of Z is positive in arm R “ 1 and negative
in arm R “ 0. Specifically β1 “ p´0.5, 0.8qJ and β0 “ p´0.5,´0.8qJ. This is not a surprise,
because 70% of the Zi in arm 1 are positive, where the quadratic function is increasing,
inducing a positive association between Y and Z, and 70% of the Zi in arm 0 are negative in
arm 0, where the quadratic function in decreasing, inducing a negative association. Therefore,
the estimated CATE score exptppβ1 ´ pβ0qJrzu « expp1.6zq would suggest that the between
group rate ratio increases with the value of z, while in fact it is a constant. This simple
example shows that misspecified regression models may create spurious treatment covariate
interactions in observational studies.
In general, assume that there is no treatment effect heterogeneity, so that
Dpzq “ exppd0q, (5)
for all z, but (1.2) are misspecified, EpY prq | Z “ zq ­“ βJr z˜. Under the Poisson regression
model, the estimator pβr is a solution to the score equation:
rSrpβq “ n´1r ÿ
Ri“r
rZi !Yi ´ exppβJ rZiq) “ 0,
where tpYi, Zi, Riq, i “ 1, ¨ ¨ ¨ , nu are observed training data, and nr is the number of patients
in arm r “ 0, 1. If řRi“r rZi rZJi is positive definite, then this solution is unique and the
estimator is well-defined. Although the regression model is mis-specified, under mild regularity
4
conditions, the resulting estimator pβr will still converge to a limit βr˚ that is the root of the
equation rsrpβq “ E „ rZi !µrpZiq ´ exppβJ rZiq) ˇˇˇˇ Ri “ r “ 0,
where µrpzq “ EpY prq | Z “ zq. If the data are from a randomized clinical trial, then rsrpβq
becomes
srpβq “ E
„ rZi !µrpZiq ´ exppβJ rZiq) .
Assumption (5) implies that β1˚ ´ β0˚ “ pd0, 0, ¨ ¨ ¨ , 0qJ, and thus, the estimated CATE score
converges to
Dpzq “ exptpβ1˚ ´ β0˚ qJrzu “ exppd0q.
This correctly suggests that there is no treatment effect heterogeneity even under mis-specified
regression models. However, in an observational study, where the observed treatment assign-
ment depends on the covariates, as the toy example above shows, in general,
rsrpβq ‰ srpβq and β1˚ ´ β0˚ ‰ pd0, 0, ¨ ¨ ¨ , 0qJ.
Consequently, pDpzq may indicate false dependence of the treatment effect on the covariates.
One lesson is that the construction of the CATE score, pDpzq, still should adjust for the
covariates imbalance, if the relevant regression models for outcomes could be misspecified.
1.4 Validation of CATE estimation models
For data from a randomized clinical trial, [30] proposed the following approach to estimate
and validate heterogeneous treatment effects. The method consists of two main steps:
1. In the training set
• assume separate regression models to link the potential outcomes Y prq in control
or treatment arm R “ r, for r “ 0, 1 (respectively) with the baseline covariates Z
to estimate the expected outcome µrpzq. Denote the prediction rules by pµrpzq.
• estimate the CATE by the difference between pµ1pzq and pµ0pzq, i.e., pDpzq “ pµ1pzq´pµ0pzq.
2. In the validation set,
• estimate ADpcq “ E
!
Y p1q ´ Y p0q | pDpZq ě c), the ATE for a subgroup of patients
tz | pDpzq ě cu,
and denote the resulting estimator by yADpcq.
• consider the validation curve
´
1´ q,yADt pH´1pqqu¯ , where q P r0, 1q and pHp¨q is
the empirical cumulative distribution function of pDpZq. Here, pH´1pqq and 1 ´ q
represent the cutoff value defining the subgroup and the proportion of patients
in the subgroup, respectively. The validation curve graphically demonstrates the
relationship between the size of the selected subgroup and the estimated ATE in
that subgroup. It can be used to assist the evaluation of pDpzq and individualized
treatment recommendation.
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• the slope of yADt pH´1pqqu is a measure reflects the quality of the scoring systempDpzq in ranking the patients according to their estimated CATE, pDpzq.
These two steps can be repeated multiple times in cross-validations for evaluating and com-
paring the performance of different scoring systems approximating the true CATE.
The small sample size of trials is one of the biggest obstacles in such analyses. Most
randomized clinical trials are designed to study the ATE, rather than the CATE. Furthermore,
to verify the CATE estimates or high value subgroup of patients for whom the treatment is
most effective, researchers use sample splitting [1] or, ideally, independent external validation
[4] to account for the exploratory nature and the overfitting tendency of relevant statistical
analysis, which further shrinks the available sample size. One important alternative is to use
observational data from real world practice. Observational data often contain more samples,
have broader target patient populations, and if collected from clinical practice, better represent
realistic clinical conditions. However, patients receiving the treatment of interest and those
receiving alternatives may be systematically different in observational data, which introduces
new challenges in statistical analysis [13].
Our goal is to generalize the method by [30] to address confounding due to differences
in baseline covariates between two treatment groups, and validate CATE estimators of the
ratio of potential outcomes. If we select the subgroup of patients with the highest true CATE
tz : Dpzq ě cu and use the ratio to measure the treatment effect,
ADtruepcq “ EtY
p1q | Dpzq ě cu
EtY p0q | Dpzq ě cu ,
then we will show that ADtruepcq is monotone in c. Consequently, if, instead, we group
patients by an estimated CATE score pDpzq and
ADpcq “ EtY
p1q | pDpzq ě cu
EtY p0q | pDpzq ě cu ,
then the trend of ADpcq is a natural measure of the quality of the CATE score. To estimate
the ATE in the subgroup of patients tz | pDpzq ě cu, one needs to adjust again for the potential
imbalances between two treatment arms using propensity score, regression or doubly robust
estimators [3, 14]. Finally, we will address these issues in details and discuss extensions to
survival outcomes.
2 Method
In this section, we propose to extend the sequence of training and validation steps by [30] to
observational studies.
2.1 Training
2.1.1 Two Regressions Approach
We first propose an approach to avoid the aforementioned spurious treatment effect hetero-
geneity with minimum model assumptions in estimating the CATE. To this end, we plan to
quantify the association between the outcome and baseline covariates in two arms via a simple
regression model, while (1) viewing the regression model as a working model approximating
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the association of interest; (2) fitting the regression model as if the potential outcomes and
covariates are observed in the entire cohort. Specifically, we propose to construct the CATE
score based on the equation srpβq “ 0 : the CATE score to be estimated is simply
exp
!
pβ1 ´ β0qJrz) ,
where βr be the (unique) solution to the estimating equation srpβq “ 0. This proposal is
appealing since Dpzq “ exppd0q implies that pβ1 ´ β0qJrz “ d0 is also a constant, i.e., there is
no spurious treatment effect heterogeneity despite the fact that the regression model µrpzq “
exppβJr rzq may be mis-specified.
It is tempting to estimate the proposed CATE score via solving empirical counterparts of
estimating equations srpβq “ 0. The challenge is that Y prq is only observed when R “ r, so we
do not observe complete data to allow us to construct these equation empirically. There are
two approaches for estimating βr. If we can construct a consistent nonparametric estimator
of µrpzq denoted by pµrpzq, then we may estimate βr by solving a simple estimating equation
n´1
nÿ
i“1
rZi "pµrpZiq ´ exp´βJ rZi¯* “ 0, r “ 0, 1.
Alternatively, under the unconfoundedness assumption (4), we can adjust the distribution of
covariates in each arm to approximate these equations by reweighitng. To be specific, instead
of solving the estimating equation above, consider the inverse probability weighted (IPW)
estimating equation
n´1
nÿ
i“1
xWiprq rZi "Yi ´ exp´βJ rZi¯* “ 0, r “ 0, 1,
where xWiprq “ r Rippi1pZiq ` p1´ rq1´Rippi0pZiq ,
and ppirpzq is an estimator for the propensity score pirpzq “ P pR “ r|Z “ zq. If unconfound-
edness (4) holds, pirpzq is bounded away from 0 and 1, and ppirpzq is uniformly consistent for
estimating pirpzq, then this IPW estimating function converges to srpβq and its root converges
to βr in probability. The aforementioned two approaches have their own limitations and we
propose to consider a more robust estimator by solving the following estimating equation
Srpβq “ n´1
nÿ
i“1
rZi !rµrpZiq ´ exppβJr rZiq) “ 0,
where rµrpzq is a special estimator of µrpzq constructed via the following steps:
1. Construct an initial non-parametric (or otherwise more flexible parametric or semi-
parametric) prediction for Y
prq
i given Zi “ z via the estimated conditional expectation
EpY prq|Z “ zq, denoted by pµrpzq;
2. Solving weighted estimating equations
n´1
nÿ
i“1
xWiprq rZiˆYi ´ exp ”αr ˆ logtpµrpZiqu ` γJr rZiı˙ “ 0, r “ 0, 1; (6)
and denote the roots by ppαr, pγJr qJ, r “ 0, 1.
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3. Let rµrpzq “ exp!pαr ˆ logppµrpZiqq ` pγJr rZi) be the “calibrated” outcome predictions
used in the estimating equation Srpβq “ 0.
This estimator is a doubly robust estimator: if either rµrp¨q is a consistent estimator of µrp¨q
or ppirp¨q is a consistent estimator of pirp¨q, then the solution to the augmented estimating
equation converges to βr, the solution of srpβq “ 0 under (4) and mild regularity conditions
[3]. The key observation is that if the propensity score is consistently estimated, the equation
(6) ensures that
E
” rZtY prq ´ rµrpZqu | rµrp¨qı “ opp1q.
If we are suspect that the Poisson regression (1.2) is mis-specified, the initial prediction rule
should be based a more flexible model than the Poisson regression that better approximates
the true model. For example, we may fit a regression model
EpY |Z,R “ rq “ exptηJr BpZqu, r “ 0, 1,
where Bpzq is a rich set of basis functions capturing the complex nonlinear relationship be-
tween Y and Z. pµrpzq “ exptpηJr Bpzqu can then be the initial prediction rule, where pηr is
the estimated regression coefficient. Alternatively, one may also employ machine learning
methods such as random forest or boosting to generate pµrpzq [11, 5].
Furthermore, we propose to employ the cross-fitting procedure to improve the finite sample
performance of the estimator by removing the correlation between rµrpZiq and Zi induced by
potential overfitting in constructing rµrpzq. Specifically, we propose to estimate βr by pβr, which
is the root of the estimating equation:
Spcfqr pβq “ n´1
Kÿ
k“1
ÿ
iPIk
rZi !rµp´kqr pZiq ´ exppβJr rZiq) “ 0,
where data are divided into K non-overlapping parts of approximately equal sizes indexed
by Ik, k “ 1, ¨ ¨ ¨ ,K, and rµp´kqr pzq is constructed using observations not in Ik. The estimated
CATE score is thus pD1pzq “ exp!ppβ1 ´ pβ0qJz) .
Remark 1. One natural question is that if rµrpzq, a high quality prediction rule for Y prqi |Zi “ z,
is already available, why do we need to reconstruct an estimator exptpβJr rzu under a mis-specified
regression model? The initial prediction rule may be a complex function of z; therefore, it is
not as transparent as that based on a simple regression model for clinical interpretation and
practical use. We can view the regression-based CATE score as a “projection” of the initial
prediction rµrpzq to a simpler functional space. This is in the same spirit of simplifying the
estimated CATE by a classification tree [16, 10].
2.1.2 Contrast Regression Approach
While motivated by the Poisson regression model, the CATE model
Dpzq “ exppδJ0 zq
arises from a more general semi-parametric model that we will study in this section. Specif-
ically, we model the conditional expectation of the potential outcomes µrpzq with the semi-
parametric regression model
EpY prq|Z “ zq “ exp
´
rδJ0 z
¯
µ0pzq, (7)
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where µ0pzq is a unknown, measurable and non-negative function in some non-parametric
function class. We assume pirpzq is unknown, but is also in a non-parametric function class.
This model represents the class of distributions for which Dpzq depends on z through δJ0 z,
and thus our goal is to estimate δ0. Under these assumptions, we provide a doubly robust
estimator of δ0 and discuss assumptions under which this estimator is
?
n-consistent.
If Y p1q and Y p0q were both observed, then δ0 is the solution to
E
„
wpZ, δqZ˜
!
Y p1q ´ exppδJZ˜qY p0q
)
“ 0, (8)
because applying the tower property of conditional expectations to (8) gives the equiva-
lent estimating equation ErwpZ, δq rZtµ1pZq ´ exppδJ rZqµ0pZqus “ 0, where wpz, δq ą 0 is
a given weight function. The solution is unique in any compact set Ω containing δ0, as
long as rZ doesn’t belong to a d or lower dimensional hyperplane and wpz, δq is bounded
above and below, for all δ P Ω and z. Like many causal inference and missing data prob-
lems, there are a variety of ways to develop estimating equations that are equivalent to
(8) under condition (4). For instance, because ErY prq | Z “ zs “ µrpzq, applying the
tower property of conditional expectations to (8) gives the equivalent estimating equation
ErwpZ, δq rZtµ1pZq ´ exppδJ rZqµ0pZqus “ 0. Equivalent inverse probability weighted estima-
tors also exist that depend on pirpzq. Because the nuisance parameters µrpzq and pirpzq are
rarely known in practice, operationalizing these estimators depends on estimating the nuisance
parameters.
Therefore, we follow the approach advocated by Robins and Rotnitzky [21] for developing
doubly robust approaches for semi-parametric models. Our estimator is closely related to
the generalized linear model with the logarithmic link function presented in their paper,
and the doubly robust estimator of the semi-parametric risk ratio model presented in [25].
Specifically, for any candidate nuisance parameters µ : Rd Ñ R and pi : Rd Ñ r0, 1s and
parameters δ P Ω Ă Rd`1, we consider the estimating function
mpG; δ, µ, piq “ rZ t1´ pipZquRY ´ pipZqp1´RqY exppδJ rZq
eδJ rZpipZq ` p1´ pipZqq
´ rZµpZq exppδJ rZq R´ pipZq
eδJ rZpipZq ` p1´ pipZqq ,
where G “ pY,R,ZJqJ.
If the propensity score is known, then substituting pi1 for pi gives the population estimating
function
E
“
mpG; δ, µ, pi1q
‰ “ E „ rZw1pZ; δ, pi1q!µ1pZq ´ µ0pZqeδJ rZ) ,
with the weight function
w1pz; δ, piq “ pipzqp1´ pipzqq
eδJrzpipzq ` 1´ pipzq ,
and δ0 is a root of the corresponding estimating equation, for any bounded choice of µ.
In the Appendix, we show that this weight function is optimal under the assumption that
Y prq | Z “ z follows a Poisson distribution with a rate of µrpzq in minimizing the variance of
the resulting estimator under the correct propensity score model pi1pzq.
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On the other hand, by re-writing the estimating function as
mpG; δ, µ, piq “ rZR!Y ´ µpZq exppδJ rZq) 1´ pipZq
eδJ rZpipZq ` p1´ pipZqq
` rZp1´Rq “Y ´ µpZq‰ exppδJ rZqpipZq
eδJ rZpipZq ` p1´ pipZqq ,
we observe that if µ0pzq “ EpY prq|Z “ zq is known, then substituting µ0 for µ gives the
population estimating equation
E
“
mpG; δ, µ0, piq
‰ “ E „ rZw1pZ; δ, piq!µ1pZq ´ µ0pZq exppδJ rZq) “ 0
for which δ0 is still a root, regardless of the choice of pipzq used. In practice, neither the
propensity score nor the conditional expectation µ0pzq is known, which motivates the plug-in
estimating equations
Snpδq “ n´1
nÿ
i“1
mpGi; δ, pµ0, ppi1q “ 0,
where Gi “ pYi, Ri, ZJi qJ, pµrpzq is an estimator for µrpzq and ppi1pzq is a estimator for the
propensity score pi1pzq. If either pµ0prq or ppi1pzq is consistent, then the solution of the estimating
equation is a consistent estimator of δ0.
In the Appendix, we prove that this estimating equation satisfies the Neyman orthogo-
nality condition [9]. Therefore, using cross-fitting with this estimating equation allows for
general use of machine learning estimators of the nuisance parameters, while still providing
accurate confidence interval coverage. To compute the cross-fitting estimator pδ0 of δ0, divide
data into K non-overlapping parts of approximately equal sizes indexed by Ik, k “ 1, . . . ,K.
Construct initial regression estimates pµp´kqr pzq of µrpzq without using observations in Ik, and
construct estimates ppip´kq1 pzq of the propensity score pi1pzq without using observations in Ik
likewise. ppip´kq0 pzq “ 1´ppip´kq1 pzq. Then, estimate δ0 by searching for the root of the estimating
equation
Spcfqn pδq “n´1
Kÿ
k“1
ÿ
iPIk
mpGi; δ, pµp´kq0 , ppip´kq1 q
“n´1
Kÿ
k“1
ÿ
iPIk
rZi
¨˚
˝Ri
”
Yi ´ exppδJ rZiqpµp´kq0 pZiqı ppip´kq0 pZiq
eδJ rZippip´kq1 pZiq ` ppip´kq0 pZiq
´p1´Riq
”
Yi ´ pµp´kq0 pZiqı exppδJ rZiqppip´kq1 pZiq
eδJ rZippip´kq1 pZiq ` ppip´kq0 pZiq ‹˛‚“ 0.
The estimator pδ is ?n-consistent and asymptotically normal under the following sufficient
assumptions (Theorem 1).
Assumption 1. (a) Z P Z, a bounded subset of Rd and the eigenvalues of ErZZJs are
between λmin ą 0 and λmax, (b) µ1pzq and µ0pzq are strictly positive and bounded on Z, (c)
There exists pi ą 0 such that pi ď pi1pzq ď 1´ pi, (d) There exists σL ą 0 and σU such that
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varpY prq | zq P rσL, σU s, z P Z, (e) for some q ą 2, Er|Y prq|q | Z “ zs ď C ă 8; (f) δ0 is a
interior point of a compact set Ω P Rd`1; and (g) pµ0, pi1q P T , which is a set of measurable
functions and there exist positive constants pi and µ such that pi ď pipzq ď 1 ´ pi, and
µ ď µpzq ď 1{µ for any pµ, piq P T .
Assumption 2. There exists n0, pi ą 0, and µ ą 0 such that for all n ą n0, (a) pi ďppipzq ď 1´ pi; (b) µ ď pµ0pzq ď 1{µ; (c) }pµ0pzq´µ0pzq}P,2`}ppi1pzq´ pi0pzq}P,2 “ oP pn´1{4q.
To specify the asymptotic distribution of the estimator pδ under aforementioned assump-
tions, let
pwp´kqpδ, Ziq “ eδJ rZippip´kq1 pZiqppip´kq0 pZiq”
eδJ rZippip´kq1 pZiq ` ppip´kq0 pZiqı2 ,
pApδq “n´1 Kÿ
k“1
ÿ
iPIk
rZi rZJi pwp´kqpδ, Ziq
$&%Yi ` pµp´kq0 pZiqppip´kq1 pZiqpRi ´ ppip´kq1 pZiqq
,.-
“n´1
Kÿ
k“1
ÿ
iPIk
rZi rZJi pwp´kqpδ, Ziq
»–RiYi ` ppip´kq0 pZiqppip´kq1 pZiqpµp´kq0 Ri ` p1´RiqtYi ´ pµp´kq0 pZiqu
fifl ,
and
pBpδq “n´1 Kÿ
k“1
ÿ
iPIk
rZi rZJi
¨˚
˝Ri
”
Yi ´ eδJ rZipµp´kq0 pZiqı
eδJ rZippip´kq1 pZiq ` ppip´kq0 pZiqppip´kq0 pZiq
´p1´Riq
”
Yi ´ pµp´kq0 pZiqı eδJ rZi
eδJ rZippip´kq1 pZiq ` ppip´kq0 pZiqppip´kq1 pZiq‹˛‚
2
.
Then, applying Theorem 3.3 from [9] under the Assumptions 1 and 2 gives
Theorem 1. Let pδ solve Spcfqn pδq “ 0. Under Assumptions 1 and 2, ?npδˆ ´ δ0q converges
weakly to a mean zero Gaussian distribution, whose variance can be consistently estimated bypAppδq´1 pBppδq pAppδq´1.
See Appendix 2 for proof. Assumption (1) provides important regularity conditions that
ensure finite, estimable parameters and nuisance parameters, and a non-degenerate asymp-
totic variance. Assumption (2) requires certain convergence rate for pµ0p¨q and ppi1p¨q in esti-
mating µ0p¨q and pi1p¨q, respectively. Under appropriate smoothness conditions for µ0pzq and
pi1pzq, there are multiple nonparametric estimators that achieve the required accuracy; see
Chernozhukov et al. [9] for a review of these estimators and their connection to cross-fit semi-
parametric estimators. The proposed estimating equation can be solved via Newton-Raphson
method. Although we can’t guarantee that the derivative matrix pApδq is positive definite in
finite samples, its limit is positive definite, with a consistent estimate of either the propensity
score or the main effect µ0pzq. We find good numerical convergence in practice, when the
sample size is adequately large.
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Remark 2. Constructing estimating equations S
pcfq
n pδq based on different random partitions
of the data and averaging the resulting solutions as the final estimator reduces the Monte-
Carlo variation due to the random splitting data into K parts. Chernozhukov et al. [9] shows
that this estimator is asymptotically equivalent to pδ analyzed above.
Remark 3. By comparing the conditional means to the baseline of µ1pzq, the semi-parametric
regression model (7) is equivalent to
E
”
Y prq | Z “ z
ı
“ expp´rδJz˜qµ1pzq,
and a similar analysis to the above gives a set of symmetric estimating equations in terms of
nuisance parameters µ1 and pi1. Averaging the resulting estimating equation with its counter-
part based on µ0 and pi1 yields two new equations:
S¯npδq “n´1
nÿ
i“1
rZiRi
»–Yi ´ eδJ rZipµ0pZiq ` pµ1pZiq
2
fifl ppi0pZiq
eδJ rZippi1pZiq ` ppi0pZiq
´
nÿ
i“1
rZip1´Riq
»–YieδJ rZi ´ eδJ rZipµ0pZiq ` pµ1pZiq
2
fifl ppi1pZiq
eδJ rZippi1pZiq ` ppi0pZiq “ 0,
and
S¯pcfqn pδq “n´1
Kÿ
k“1
ÿ
iPIk
¨˚
˝ rZiRi
”
Yi ´ teδJ rZipµp´kq0 pZiq ` pµp´kq1 pZiqu{2ı
eδJ rZippip´kq1 pZiq ` ppip´kq0 pZiq ppip´kq0 pZiq
´ rZip1´Riq
”
Yie
δJ rZi ´ teδJ rZipµp´kq0 pZiq ` pµp´kq1 pZiqu{2ı
eδJ rZippip´kq1 pZiq ` ppip´kq0 pZiq ppip´kq1 pZiq‹˛‚“ 0.
In practice, we recommend to solve S¯
pcfq
n pδq “ 0 for estimating δ0 due to the symmetry between
µ1 and µ0.
2.2 Validation
In the validation step, we rank the patients in the validation set according to the estimated
CATE score pDpzq and estimate the ATE in the subgroup of patients with the most promising
CATE scores, tz | pDpzq ě cu. [30] considered Dpzq “ EpY p1q ´ Y p0q | Z “ zq and ADpcq “
EpY p1q ´ Y p0q|DpZq ě cq. In such a case, ADpcq, the ATE in tz | Dpzq ě cu, is a monotone
increasing function of c. The following theorem ensures that for CATE measured by the ratio
of µrpzq, as in the NTD example, ADpcq is also monotone increasing.
Theorem 2. For nonnegative potential outcomes Y prq, r “ 0, 1, Let
Dpzq “ EpY
p1q | Z “ zq
EpY p0q | Z “ zq
and
ADpcq “ EpY
p1q | Dpzq ě cq
EpY p0q | Dpzq ě cq .
If all involved expectations are finite and 0 ă DpZq ă 8 for almost every Z, ADpcq is
monotone increasing in c, and ADpcq ě c for any c.
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See Appendix 3 for detailed proof. Therefore, if we measure treatment effects by the ratio,
we still can evaluate the quality of the constructed CATE scoring system by examining the
“slope” of the curve yADpcq. Because, ADpcq ě c, for any c, if Dpzq is the true CATE, the
ATE in the subgroup consisting of patients with promising CATEs tends to be promising as
well.
Remark 4. The monotonicity of ADpcq depends on the metric used to measure the treatment
effect. For example, ADpcq is not necessarily monotone increasing if the treatment effect is
measured by odds ratio (OR) for binary outcomes. The general problem is that the ATE
in a subgroup of patients with the largest CATE may not be large if the treatment effect is
measured by a contrast that is more complex than the ratio or difference. In Appendix 3, we
have provided a simple example where the marginal OR of a subgroup of patients with highest
conditional OR is not the highest.
To estimate ADpcq using observational data, we need to account for potential imbal-
ances in baseline covariates between two arms, since the treatment assignment is not ran-
domized. There are various ways to estimate the ATE in an observational study and all
involve certain model assumptions. To construct a doubly robust approach, suppose that
the validation set consists of m, independent identically distributed copies of pY V , RV , ZV q,!
pY Vi , RVi , ZVi q, i “ 1, ¨ ¨ ¨ ,m
)
, where the superscript V indicates membership in the valida-
tion set. Then, estimate ADpcq as follows: first estimate µrpzq by pµrcpzq in the subgroup of
patients tzV | DˆpzV q ě cu; and then estimate EpY prq | pDpZV q ě cq by
pµrpcq “ m´1c ÿpDpZVi qěc
„pµcrpZVi q `xW Vi pr, cq!Y Vi ´ pµcrpZVi q) ,
where xW Vi pr, cq “ r RVippic1pZVi q ` p1´ rq 1´R
V
ippic0pZVi q ,ppicrpzq is the estimator for pirpzq in the subgroup tzV | pDpzV q ě cu from the validation set,
and mc is the subgroup size. Finally, let yADpcq be the simple plug-in estimator pµ1pcq{pµ0pcq.
This estimator is consistent for ADpcq, if either the propensity score or the main effect µrpzq
is consistently estimated. One advantage of this approach is that it not only provides an esti-
mator for the ATE measured by the rate ratio but also the rates themselves, which facilitates
our interpretation of the effect size.
2.3 Time-to-Event Outcomes
In precision medicine, one important type of clinically meaningful outcomes to model is time-
to-event outcome. For example, among MS patients in the NTD registry, a useful endpoint
to measure effectiveness is the time to first relapse. In this case, the observed training data
consist of tpXi,∆i, Ri, Ziq, i “ 1, ¨ ¨ ¨ , nu, where Xi “ Ti ^ Ci, ∆i “ IpTi ă Ciq, Ti is the
event time of interest and Ci is the censoring time. As previously, we will use T
prq
i and C
prq
i
to refer to the potential event time and censoring time under treatment r. For time-to-event
outcomes, the heterogeneous treatment effect often cannot be measured by a contrast of the
conditional expectations EpT prq|Z “ zq, because this expectation may not be identifiable due
to right censoring.
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It is a popular practice to employ Cox proportional hazards model to analyze time-to-
event outcomes. Let λrpt | zq be the hazard function of T prqi | Zi “ z, r “ 0, 1. The Cox
proportional hazards model assumes that
λrpt | zq “ λr0ptq exppβJr zq,
for λr0p¨q, an unspecified baseline hazard function in group r. In this case, exptpβ1 ´ β0qJzu
is a natural measure of the CATE. If the proportional hazards assumption is violated, we can
still define βr as the root of the limit of the score equation of the Cox model. However, in this
case, exptpβ1 ´ β0qJzu may no longer be a sensible surrogate for the CATE even if two arms
have the same covariate distribution, as it may introduce spurious heterogeneity not present
in real data. We provide an example in Appendix 3. The parameter closest to the mean
survival time and still estimable is the restricted mean survival time, i.e., EpT ^ τq. Then,
the ATE (and CATE) are an appropriate contrast of restricted mean survival time.
In this section, we propose to use the ratio of restricted mean time lost (RMTL) due to
the first relapse to measure the treatment effect, i.e.,
Dpzq “ Etτ ´ pT
p1q ^ τq|Z “ zu
Etτ ´ pT p0q ^ τq | Z “ zu ,
where τ ą 0 is a chosen constant [24], since it is expected to be concordant with the relapse
rate ratio. When the relapse rate is low, this ratio is similar to the hazard ratio.
To approximate this CATE, we consider the score exptpβ1 ´ β0qJrzu, where βr is the root
of the the equation
E
„ rZ !Epτ ´ T prq ^ τ | Zq ´ exppβJr rZq) “ 0.
While this regression model is not always natural for arbitrary choices of τ , it can still be a
useful working model. For example, when T prq | Z “ z follows an exponential distribution
with the failure rate of βJr rz and τ is large relative to βJr rZ, this model is approximately
correctly specified. Luckily, like the Poisson regression model discussed above, this approach
is robust to mis-specification of the model in the sense that it doesn’t introduce spurious
treatment effect heterogeneity. Therefore, it remains a useful working model for estimating
heterogeneous treatment effects measured by RMTL ratio.
Again, we propose two approaches for approximating Dpzq. In the first approach, we
estimate βr by solving the estimating equation based on cross-fitting:
n´1
Kÿ
k“1
ÿ
iPIk
rZi ”rµp´kqr pZi, τq ´ exppβJr rZiqı “ 0,
where rµp´kqr pz; τq is an estimator of Epτ ´T prq^ τ | Z “ zq constructed via the following step
1. Construct an initial estimator of Epτ ´ T prqi ^ τ |Zi “ zq based on observations not in
Ik. denote the estimator by pµp´kqr pz; τq.
2. Solving weighted estimating equationsÿ
iRIk
pLiprqxW p´kqi prq rZi „pτ ´ Ti ^ τq ´ exp!αr ˆ logppµp´kqr pZi, τqq ` γJr rZi) “ 0,
and denote the roots by ppαp´kqr , pγp´kqJr qJ, r “ 0, 1.
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3. Let rµp´kqr pz; τq “ exp!pαp´kqr ˆ logppµp´kqr pZi, τqq ` pγp´kqJr rZi) .
In the second step of constructing rµp´kqr p¨, τq,
pLiprq “ IpTi ^ τ ă CiqpKCrpTi ^ τ | Ziq
and xW p´kqi prq “ r Rippip´kq1 pZiq ` p1´ rq
1´Rippip´kq0 pZiq ,
where IpTi^ τ ă Ciq “ ∆i`p1´∆iqIpXi ě τq, and pKCrp¨ | zq is an estimator of the survival
function of the censoring time C
prq
i | Zi “ z under a regression model, such as the Cox model.
The key assumption here is that the inverse probability weighting via pLiprq can correct the
effect of right censoring, as long as pKCrpt | zq is a consistent estimator of the survival function
of the censoring time Cprq given Z “ z and P pCprq ą τ |Z “ zq ě τ ą 0. Let the resulting
estimator of βr be denoted by pβr and Dpzq can be approximated by exptpβ1 ´ pβ0qJzu.
Remark 5. The initial estimator pµp´kqr pz; τq can be based on any sensible regression models
characterizing the relationship between T
prq
i and Zi. For example, one may employ the standard
Cox model λrpt | zq “ λr0ptq exptηJr Bpzqu. Under this model,
τ ´
ż τ
0
exp
”
´pΛr0ptq exptpηJr Bpzquı dt
can be used to approximate Epτ ´ T prqi ^ τ |Zi “ zq, where pΛr0ptq is the Breslow estimator for
the cumulative baseline hazard function and pηr is the maximum partial likelihood estimator
for ηr in arm r [8]. Alternatively, we may assume a regression model tailored for restricted
mean survival time [22]:
EpT prq ^ τ |Z “ zq “ τ exptη
J
r Bpzqu
1` exptηJr Bpzqu
and estimate ηr by solving the simple estimating equation
nÿ
i“1
IpRi “ rqpLiprqBpZiq#Ti ^ τ ´ τ exptηJr BpZiqu
1` exptηJr BpZiqu
+
“ 0.
Under this model, Epτ ´ T prqi ^ τ |Zi “ zq can be approximated by
τ
1` exptpηJr Bpzqu ,
where pηr is the root to the estimating equation above.
In the second approach, we may directly estimate δ0 under the assumption that Dpzq “
exppδJ0 zq. Specifically, we estimate δ0 by solving the estimating equation by cross-fitting
n´1
Kÿ
k“1
ÿ
iPIk
pLipRiq
¨˚
˝ rZiRi
”
pτ ´ Ti ^ τq ´ eδJ rZipµp´kq0 pZi; τqı
eδJ rZippip´kq1 pZiq ` ppip´kq0 pZiq ppip´kq0 pZiq
´ rZip1´Riq
”
pτ ´ Ti ^ τq ´ pµp´kq0 pZi; τqı eδJ rZi
eδJ rZippip´kq1 pZiq ` ppip´kq0 pZiq ppip´kq1 pZiq‹˛‚“ 0,
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or the counterpart of S¯
pcfq
n pδq “ 0. Let the root of the equation be pδ. Similar to the count
outcome, pδ is a consistent estimator of δ0, if either the propensity score estimator ppi1pzq or the
outcome predictions pµp´kq0 pz; τq is consistent. Lastly, Dpzq can be approximated by expppδJzq.
Note that the effect of right censoring is corrected by the weight pLipRiq.
With an estimator pDpzq of the CATE, we need to estimate
ADpcq “ Etτ ´ T
p1q ^ τ | pDpZq ě cu
Etτ ´ T p0q ^ τ | pDpZq ě cu
based on validation data. To this end, We may estimate the ADpcq by constructing doubly
robust estimators for Epτ ´ T prq ^ τ | pDpZq ě cq, r “ 0, 1. To this end, we may construct an
initial estimator for µrpz, τq “ Epτ ´ T prq ^ τ |Z “ zq using observations in the subgroup
tzV | pDpzV q ě cu. Methods described in Remark 5 can be used to achieve this objective.
Denote the resulting estimator by pµcrpz; τq. We may estimate Epτ ´ T prq ^ τ | pDpZq ě cq by
m´1c
ÿ
pDpZVi qěc
„pµcrpZVi , τq ` pLVciprqxW Vci prq!pτ ´ T Vi ^ τq ´ pµcrpZVi , τq) .
Then, we propose to estimate ADpcq by the plugin estimator
pµ1pc; τqpµ0pc; τq .
3 Numeric Simulation
In this section, we conduct a numerical study to investigate the finite sample performance of
the proposed method. In the first set of simulations, we simulate the outcomes F prq | Z “ z
and Y prq | F prq “ f, Z “ z from a uniform distribution over r0, 0.75s and a Poisson distribution
Poistµrpzqfu, respectively. With slightly abuse of notations, Zi (or zi) stands for the i-
th component of the covariate vector Z (or z) rather than the covariate vector of the i-th
patient. The 10-dimensional covariate Z is generated from a multivariate Gaussian, where
the first 5 components are independent and the last 5 components are correlated with a
common correlation coefficient of 0.5 but independent of the first 5 components. The marginal
distribution of Zi is standard Gaussian. To ensure that the propensity score is bounded
away from 0 and 1, any Zi greater than 2 (or less than ´2) is replaced by 2 (or ´2). The
treatment assignment R|Z “ z is generated from a Bernoulli distribution with a probability
of pi1pzq “
 
1` exppz1 ` 0.5z2 ´ 0.5z6q
(´1
. There are six different settings:
1. The true CATE: Dpzq “ expp0.75` 0.125z1 ` 0.05|z2 ` 0.5| ´ 0.25z6q with
µ1pzq “ exp
`
0.375` g1pz1, z2, z6q ` 0.30|z2 ` 0.5|
˘
µ0pzq “ exp
`´0.375` g2pz1, z2, z6q ` 0.25|z2 ` 0.5|˘ ;
2. The optimal CATE: Dpzq “ expp0.775` 0.125z1 ` 0.05z2 ´ 0.25z6q with
µ1pzq “ exp
`
0.525` g1pz1, z2, z6q ` 0.30z2
˘
µ0pzq “ exp
`´0.250` g2pz1, z2, z6q ` 0.25z2˘ ;
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3. The optimal CATE is expp0.025` 0.125z1 ` 0.05z2 ´ 0.25z6q with
µ1pzq “ exp p0.525` 0.125z1 ` 0.30z2 ` 0.25z6q
µ0pzq “ exp p0.5` 0.25z2 ` 0.50z6q ;
4. The same as setting 1, but the analysis only uses first five covariates, i.e., Z1, ¨ ¨ ¨ , Z5;
5. The true CATE: Dpzq “ expp0.125z1 ` 0.05|z2 ` 0.5| ´ 0.25z6q with
µ1pzq “ exp
`
g1pz1, z2, z6q ` 0.30|z2 ` 0.5|
˘
µ0pzq “ exp
`
g2pz1, z2, z6q ` 0.25|z2 ` 0.5|
˘
;
6. The optimal CATE: Dpzq “ expp0.025` 0.125z1 ` 0.05z2 ´ 0.25z6q with
µ1pzq “ exp
`
0.15` g1pz1, z2, z6q ` 0.30z2
˘
µ0pzq “ exp
`
0.125` g2pz1, z2, z6q ` 0.25z2
˘
,
where g1pz1, z2, z6q “ 0.125z1` 0.5|z1| ` 0.5|z2| ` 0.25z6 and g2pz1, z2, z6q “ 0.5|z1| ` 0.5|z2| `
0.5z6. In the first setting, the simple Poisson regressions with a linear predictor are misspecified
in both arms and the log-transformed optimal CATE is not a linear function of Z either. The
proposed contrast regression is appropriate for the second setting, where the Poisson regression
is mis-specified, but the underlying log-transformed CATE is a linear combination of the
baseline covariates. The third setting is ideal for the simple regression approach, since the
Poisson regression models are correctly specified in both arms. The fourth setting is the same
as the first setting. However, since we omit the last five covariates, Z6 represents unmeasured
confounding in the analysis. In this setting, the propensity score model is also misspecified.
The fifth and sixth settings are similar to the first and second settings, respectively, except
that the ATEs in the entire cohort are close to the null. In those settings, we expect that
the CATE based on EpY p1q ´ Y p0q | Z “ zq is positively correlated with that based on
Dpzq “ EpY p1q | Z “ zq{EpY p0q | Z “ zq.
For each simulated data set with a sample size of n “ 2, 000, we construct the CATE score
using six methods.
1. the first method employs the boosting method (the base learner is the regression tree
of depth 2) to estimate µrpzq in each arm separately and the CATE score is the ratio
of two estimators;
2. the second method fits a na¨ıve Poisson regression model in each arm;
3. the third method uses Bayesian additive regression tree to estimate µrpzq and the CATE
score is the difference of two estimators [17];
4. the fourth method uses boosting method to predict the modified outcome [27]
Y
F
"
Rppi1pZq ´ p1´Rqppi0pZq
*
;
5. the fifth method is the proposed twin regression with the proposed doubly robust ad-
justment (the boosting-based estimation of µrpzq serves as the initial predictor);
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6. the sixth method is the proposed contrast regression targeting Dpzq directly also with
the doubly robust adjustment.
The propensity score is always estimated by fitting a standard logistic regression model. We
then calculate the true ADtHˆ´1pqqu and the validation curve, p1 ´ q, ADt pH´1pqquq, based
on constructed CATE scores. We have also calculated the correlation coefficients between the
estimated CATE score and the true CATE (after log-transformation). After repeating this
process 200 times, we summarize the performance of each method based on the average of
the resulting validation curves ( Figure 1). We also include the validation curve based on the
true CATE as the benchmark. Figure 2 shows the distribution of the correlation coefficients
between the estimated CATE score and the truth. In addition, for settings 2, 3 and 6, model
7 is correctly specified and pδ from the contrast regression is a consistent estimator of δ0. We
also examine the empirical bias and the coverage level of 95% confidence interval in estimating
δ0 based on 400 replications. The results are summarized in Table 3.
In settings 1, 2, 5 and 6, the proposed methods generates the best CATE score based
on the validation curve. The CATE score based on the simple regression (method 2) is not
informative and sometimes even yields a wrong direction due to the confounding effect. The
CATE score based on nonparametric boosting (method 1) has robust performance but is
slightly inferior to the proposed methods, despite the fact that CATE score from the latter is
much simpler. The two methods (3 and 4) targeting CATE measured by the difference rather
than ratio of µrpzq perform the worst in settings 1 and 2 and slightly better in settings 5 and
6. But in neither case, their performance is satisfactory, implying that the estimation method
needs to be tailored for the metric used to measure the treatment effect. In setting 3, the
na¨ıve regression performs the best, since the simple regression model is correctly specified. The
boosting and two proposed methods are only slightly inferior to the na¨ıve regression. In setting
4, where the propensity score model is mis-specified and there is unmeasured confounding,
neither method performs well. The proposed methods still perform relatively better than
others. In settings 2, 3 and 6, where Dpzq “ exppδJ0 zq, the proposed estimator based on the
contrast regression is almost unbiased and the empirical coverage level of the constructed 95%
confidence interval is close to the nominal level (Table 3).
In the second set of simulations, we consider the survival outcomes: T prq | Z “ z is gen-
erated from an exponential distribution with a failure rate λrpzq. The censoring distribution
Cprq | Z “ z is the minimum of a uniform random variable over [0.5, 1] and an exponential
random variable with a failure rate of expp0.25 ` z3q. The treatment assignment R | z is a
Bernoulli random variable with a probability of pi1pzq “
 
1` expp´z1 ` 0.5z2 ` 0.5z6q
(´1
.
Other than right censoring, the only significant difference from the first set of simulations is
that the simple multiplicative model for µrpzq or Dpzq is always misspecified. Due to the
anticipated similarity to the previous simulations, we only consider the following two settings:
1. The optimal CATE is approximately expp´0.08` 0.34z1 ` 0.11z2 ` 0.43z6q
λ1pzq “ exp
`´0.35` 0.125z1 ` 0.3z2 ` 0.5z6 ´ 0.5|z1| ` 0.5|z2|˘
λ0pzq “ exp
`´0.375` 0.25z2 ` 0.25z6 ´ 0.5|z1| ` 0.5|z2|˘
2. The optimal CATE is approximately expp´0.09` 0.27z1 ` 0.10z2 ` 0.51z6q with
λ1pzq “ exp p´0.05` 0.125z1 ` 0.3z2 ` 0.5z6q
λ0pzq “ exp p´0.075` 0.25z2 ` 0.25z6q
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In both settings, log-transformed true CATE is not equal to, but can be approximated by a
linear combination of the covariates, which can explain approximately 85% of the variation
in log-transformed true CATE. τ0 “ 0.75 in RMTL and the censoring rate is 83% in both
settings. In the light of the first set of simulations, we construct the CATE score only using
four methods: (1) the first method employs the boosting method coupled with IPW correcting
for right censoring to estimate µrpz, τq in each arm separately; (2) the second method fits
a simple multiplicative regression model µrpz, τq “ exppβJr rzq in each arm; and the third
and fourth methods implement our new proposals. The censoring probability in the IPW is
estimated via a Cox regression model, which is misspecified. Again, we calculate the the true
validation curve based on constructed CATE scores and the correlation coefficients between
the estimated CATE score and the true CATE after log-transformation. After repeating this
process 200 times, we summarize the performance of each method based on the average of
the resulting validation curves and the distribution of correlation coefficients between the
estimated and true CATEs in Figure 3.
In the first setting, the two proposed methods generate the best CATE score based on ei-
ther the validation curve or the distribution of correlation coefficients. The estimated CATE
score based on na¨ıve regression or boosting is not informative. In setting two, where the
multiplicative regression model is approximately correct within arm, the na¨ıve regression ap-
proach performs the best, as expected. The twin regression performs almost equally well.
Both boosting and contrast regression also yield informative CATE scores for subgroup iden-
tification. In general, the simulation results are consistent with those from the first set of
simulations.
4 Example
This project includes real-world data from 2791 patients from the NTD MS registry with 1050
patients receiving TERI and 1741 patients receiving DMF. Covariates of interest include age,
number of prior treatments, MS duration, prior usage of glatiramer acetate (GA), prior usage
of interferon (IFN), number of relapses in the year and in the two years prior to the index
therapy, baseline Expanded Disability Status Scale (EDSS), and baseline pyramidal EDSS
score. In Table 1, we summarize the distribution of aforementioned covariates by treatment
arm. The patients receiving TERI are different from patients receiving DMF in several key
patients’ characteristics. For example, the patients receiving TERI tend to be older (45 vs
40), with a longer disease duration (8.1 years vs. 6.6 years) and have higher EDSS scores
(2.03 vs 1.84) than those receiving DMF.
In the entire cohort, the direct comparison of the normalized relapse rate based on Poisson
regression shows that patients receiving DMF have a significantly lower relapse rate than
those receiving TERI. The estimated ratio of the relapse rate (TERI vs DMF) is 1.270 (95%
confidence interval: 1.121-1.439, p ă 0.001q. After our adjusting the imbalances in baseline
covariates using the doubly robust estimation procedure, the estimated relapse rate ratio is
1.299 with a slightly wider confidence interval (1.018, 1.658). The adjusted annual relapse
rate is 0.308 for TERI and 0.237 for DMF. We implemented the standard regression, and
the two proposed methods to construct the CATE scores approximating the “individualized”
relapse rate ratio. To implement the proposed procedure, we used the boosting method for
Poisson distribution to construct an initial predictor of the relapse rate, with a depth of 2 for
each individual tree and the number of trees selected via 5-fold cross-validation. The proposed
CATE score is based on the average of three replicates of 7-fold cross-fitting. The propensity
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score is constructed based on the standard logistic regression model. The log-transformed
CATE score is a linear combination of baseline covariates, with the weights summarized in
Table 2, which also includes the estimated standard error for the weights of covariates in
CATE score from the contrast regression, suggesting that GA, number of relapses in the year
prior to the therapy, the number of relapses in two years prior to the therapy and baseline
EDSS are statistically significant at the 0.05 level in the CATE score. The composition of the
CATE score based on the na¨ıve Poisson regression is different from that based on two new
proposals. For example, the weight of EDSS from the na¨ıve approach is substantially smaller
than those in new CATE scores. Figure 4 shows a scatter plot of these three CATE scores
in the entire cohort, demonstrating a positive correlation but also ample differences between
the na¨ıve and new CATE scores. On the other hand, the two new CATE scores are highly
concordant.
We use cross validation to compare and evaluate the performance of the CATE scores more
objectively. To this end, we considered four CATE scores: a score based on predicted relapse
rates using boosting method, a score based on na¨ıve Poisson regression, and two scores based
on our new proposal with the boosting-based prediction as the initial prediction. In each
iteration of cross-validation, the entire data are split into a training set (67%) and a testing
set (33%). We estimate the CATE scores based on training set and construct the validation
curves in the testing set. After repeating this process 50 times, the empirical median of
all 50 validation curves is obtained to measure the performance of the corresponding CATE
score. Figure 5 (the upper row) summarizes the results, where we plot the median validation
curves in both the training and testing sets to demonstrate the differential performance of four
CATE scores. The two proposed CATE scores adjusting for imbalance in baseline covariates
appear to have a similarly superior performance in the testing set: both scores suggest a
moderate treatment effect heterogeneity. In the aforementioned cross-validation, we also use
the estimated CATE score based on the training data to split the patients in the testing set into
two group of equal sizes. Then, we estimate the ratio of average relapse rates in two subgroups
separately. If the constructed CATE score is informative, then we expected that the estimated
rate ratio in the subgroup of patients with a higher CATE score is also higher. The median
of the estimated ratios of the relapse rate (TERI vs DMF) is 1.723 in 50% patients having
a CATE score favoring DMF the most and the median of the estimated ratios of the relapse
rate is 1.089 in remaining 50% patients based on the twin regression method. These two
median ratios become 1.671 and 1.113 based on the CATE score constructed via the contrast
regression method. The distribution of the estimated ratios across different cross-validation
replicates are summarized in Figure 6. As a cautionary note, this observed difference in
treatment effect may not be adequately stable due to the limited sample size in the validation
set (on average, there are only 465 patients in each of the two subgroups). However, the results
still exhibit moderate signals of the presence of treatment effect heterogeneity captured by
two proposed approaches. A important observation is that the estimated treatment effect
heterogeneity doesn’t alter the recommendation of the treatment, since DMF appears to be
superior to TERI in most if not all of the patients in terms of reducing relapse rate, although
the relative benefit may vary in different subgroups. In future studies, it would be beneficial
to have an independent cohort for further validation of the constructed CATE score.
In the analysis of the time to the first relapse, we use the ratio of RMTL due to relapse as
the metric for the treatment effect, with a truncation time point τ0 of 4.34 years (52 months).
In the na¨ıve comparison without adjusting for baseline covariates, the estimated ratio of
mean time lost up to 4.34 years is 1.246 (95% confidence interval: 1.098-1.414, p ă 0.001),
suggesting that time lost to relapse in patients receiving DMF is only 80% of that in patients
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receiving TERI. After the doubly robust adjustment, the estimated ratio becomes 1.531 (95%
confidence interval: 1.313-1.785, p ă 0.001) with the RMTL of 1.451 and 0.947 years for TERI
and DMF, respectively, showing a greater difference between two treatments. We compare
CATE scores based on the na¨ıve regression and new proposal. In constructing the proposed
CATE scores, we used random forest with 50 trees to generate the initial prediction of the
RMTL due to relapse. The log-transformed CATE score is a linear combination of baseline
covariates, whose composition is also reported in Table 2. While the contributions of the
same covariate to resulting CATE scores can be different, such as the EDSS score at baseline,
the resulting CATE scores are correlated. We also performed cross validation to evaluate the
performance of the different CATE scores. It appears that the CATE score directly based
on boosting overfits the training data and performs similarly as other methods in the testing
set. However, the estimated treatment effect heterogeneity is very weak based on any of the
four CATE scores. For example, in the cross-validation, the estimated ratio of RMTL in 50%
of the patients favoring DMF based on contrast regression approach is 1.624. The ratio in
the rest of the 50% patients is 1.460, only marginally lower. The distributions of two RMTL
ratios across replicates substantially overlap. Lastly, we examine the relationship between the
CATE scores built for the number of relapses and the time to the first relapse. The two sets
of CATE scores are correlated as expected. For example the correlation coefficient between
two CATE scores based on the contrast regression is 0.80.
5 Discussion
We extend the regression approach by [30] to develop a precision medicine strategy from
observational data. There are three important messages learned in this practice. First, the
metric for the treatment effect has an important impact on the estimation and validation of
CATE. The difference or ratio of the expected response from individual patients may be the
most common choice. While we justify that the ATE based ratio or difference in patients with
big CATE must also be big, this is not necessarily true for treatment effect measured by OR or
hazard ratio. In other words, the ATE and CATE don’t always align with each other. When
we are interested in treatment effect measured by the OR or hazard ratio, we may not want
to identify the high value subgroup according to the CATE on the same metric. Second, the
difference in covariates distribution between patients receiving different treatments affects the
regression analysis within each arm and the standard methods may induce false treatment-
covariate interaction. By borrowing appropriate techniques developed for estimating ATE
in causal inference to adjust the standard estimation procedure, we eliminate the spurious
heterogeneity caused by the imbalance in covariates. Lastly, we proposed a set of methods for
estimating the CATE measured by the ratio, which may result in very different conclusions
in comparison with most current methods, which target on the difference as the treatment
effect.
We note that in this work, we have assumed that training and validation sets follow
the same distribution. If the distribution of the validation set or the target population is
different from that of the training set, the proposed estimation procedures of CATE need
to be modified with a new arm specific propensity score being constructed to match the
distribution of covariates of the patients in the treatment arm r of the training set to that of
the target population. Otherwise, the same CATE score may define a different subgroup of
patients in the target population, i.e., tz | pDpzq ě cu may be different from tzV | pDpzV q ě cu.
Consequently, the ATE observed in the high value subgroup tz | pDpzq ě cu may not be
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reproducible. Furthermore, the validity of the validation results still depends on assumptions
made in estimating the causal effect based on observational data. Ideally, the validation
data are from an external randomized clinical trial, so that we can estimate the ATE in the
identified high value subgroup without systematic biases from even unmeasured confounding.
Qi et al. [20] discuss the optimal treatment recommendation in the presence of K ą 2
treatments. The proposed twin regression approach can be used to approximate µkpzq “
EpY prq | Z “ zq, k “ 0, 1, ¨ ¨ ¨ ,K, and select the optimal regiment accordingly. The con-
trast regression can directly estimate Dijpzq “ µipzq{µjpzq based on the limiting estimating
equation:
E
»—–wpZ, δq rZ
$&%ź
k‰i
pikpZqIpR “ iqY ´
ź
k‰j
pikpZqIpR “ jqY exppδJ rZq
,.-
fiffifl “ 0
for estimating Dijpzq “ exppδJijrzq, where pikpzq “ P pR “ k | Z “ zq and wpz, δijq is a weight
function. Appropriate augmentation term based on tpIpR “ rq ´ pirpZq, r “ 1, ¨ ¨ ¨ ,Ku can
be introduced for further efficiency improvement. A complication is that resulting estimators
don’t necessarily have the property that Dijpzq “ DilpzqDljpzq, for which further research is
warranted.
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Table 1: Baseline characteristics of RRMS patients at the initiation of therapy with DMF
and TERI: mean (standard deviation) for continuous covariate and number (proportion) for
binary covariate
variable TERI pn “ 1050q DMF pn “ 1741q p value
exposure time (year) 2.11(1.71) 2.17(1.72) 0.603
age 44.86(10.20) 39.91(10.74) 0.0000
# prior treatments 0.97(0.93) 0.96(0.98) 0.4703
MS duration (year) 8.11(7.64) 6.57(6.60) 0.0000
GA 821(78.2%) 1327(76.2%) 0.246
IFN 502(47.8%) 886(50.9%) 0.118
# relapses (prior year) 0.42(0.60) 0.46(0.65) 0.2032
# relapses (prior 2 years) 0.64(0.84) 0.71(0.90) 0.095
EDSS 2.03(1.51) 1.84(1.50) 0.0006
pyramidal EDSS 0.92(1.10) 0.77(1.04) 0.0000
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Table 2: The estimated weights in constructed CATE scores (TERI vs DMF)
ratio of relapse rate ratio of RMTL
na¨ıve reg. twin reg. contrast reg. na¨ıve reg. twin reg. contrast reg.
intercept 0.692 0.476 0.670 p0.711q˚ 1.061 1.310 1.017
age 0.013 0.013 0.017 (0.013) 0.008 0.011 0.010
# prior treatments -0.303 0.011 -0.088 (0.195) -0.255 -0.342 -0.210
MS duration 0.022 0.045 0.028 (0.028) 0.004 0.003 0.007
(years)
GA -0.584 0.517 -0.700 (0.349) -0.630 -0.801 -0.640
IFN -0.304 -0.024 -0.185 (0.318) -0.390 -0.583 -0.410
# relapses -0.258 -0.661 -0.811 (0.271) -0.217 -0.193 -0.126
(prior year)
# relapses 0.191 0.360 0.444 (0.201) 0.195 0.139 0.130
(prior two years)
EDSS -0.046 -0.247 -0.233 (0.114) -0.072 -0.060 -0.117
pyramidal EDSS 0.006 0.027 -0.004 (0.160) 0.060 0.030 0.073
˚ : the estimated standard error of the weight.
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Table 3: Empirical bias and coverage level of the 95% confidence interval in estimating δ0
based on 400 replications under three different settings: pδ0 “ pδ00, δ01, δ02, ¨ ¨ ¨ , δ10qJq
Covariate Setting 2 Setting 3 Setting 6
bias coverage bias coverage bias coverage
δ01 “ 0.125 -0.018 92.5% -0.030 94.5% -0.014 94.0%
δ02 “ 0.05 -0.015 92.5% -0.014 92.8% -0.013 90.8%
δ03 “ 0 0.004 93.8% 0.002 94.2% -0.002 94.2%
δ04 “ 0 -0.002 94.0% 0.002 93.8% 0.004 94.8%
δ05 “ 0 -0.005 94.5% -0.004 93.0% -0.007 93.8%
δ06 “ ´0.25 0.013 91.5% 0.008 94.2% 0.016 93.2%
δ07 “ 0 -0.004 93.0% 0.008 91.8% 0.002 93.8%
δ08 “ 0 -0.002 94.5% -0.003 93.0% 0.000 92.8%
δ09 “ 0 0.005 92.5% 0.000 93.8% -0.011 93.2%
δ10 “ 0 -0.006 92.0% -0.007 93.5% -0.004 91.8%
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Figure 1: The ATE in subgroups of patients identified by different CATE scores including
true CATE, boosting (method 1), na¨ıve regression (method 2), Bayesian additive regression
tree (method 3), modified outcome boosting (method 4), twin regression (method 5), contrast
regression (method 6) in six simulation settings.
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Figure 2: The distribution of correlation coefficients between estimated CATE and true CATE
in six simulation settings; there are six methods considered: boosting, na¨ıve regression,
Bayesian additive regression tree, modified outcome boosting, twin regression (light gray),
and contrast regression (dark gray)
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Figure 3: The first row: the ATE in subgroups of patients identified by different CATE scores
(boosting, standard regression and the proposed methods) in two simulation settings and the
ATE in subgroup of patients sorted according to the true Dpzq (solid curve); the second row:
the distribution of correlation coefficients between true CATE and estimated CATE scores
including that based on twin regression (light gray) and contrast regression (dark gray)
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Figure 4: The log-transformed CATE scores based on the standard regression approach and
the proposed doubly robust adjustment method: CATE for the ratio of relapse rates
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Figure 5: The ATE in subgroups of patients based on the CATE scores constructed in the
training set (machine learning, na¨ıve regression and two proposed methods) in the NTD
registry: relapse rate ratio of TERI vs DMF for the number of relapses (the first row); RMTL
ratio of TERI vs DMF for the time to the first relapse (the second row)
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Figure 6: The cross-validated ATE (TERI vs DMF) of subgroups of patients identified by
different CATE scores (machine learning, na¨ıve regression and the proposed method) in the
NTD registry. relapse rate ratio of TERI vs DMF for the number of relapses (the first row);
RMTL ratio of TERI vs DMF for the time to the first relapse (the second row); gray box:
the subgroup with higher CATE score; empty box: the subgroup with lower CATE score.
l
1 2
1.
0
1.
5
2.
0
2.
5
3.
0
boosting
AT
E 
(R
R 
rat
io
)
l
l
l
l
l
1 2
1.
0
1.
5
2.
0
2.
5
3.
0
naive reg
AT
E 
(R
R 
rat
io
)
1 2
1.
0
1.
5
2.
0
2.
5
3.
0
twin reg
AT
E 
(R
R 
rat
io
)
1 2
1.
0
1.
5
2.
0
2.
5
3.
0
contrast reg
AT
E 
(R
R 
rat
io
)
l
ll
1 2
1.
0
1.
2
1.
4
1.
6
1.
8
2.
0
random forest
AT
E 
(R
ML
T 
ra
tio
)
l
l
1 2
1.
0
1.
2
1.
4
1.
6
1.
8
2.
0
naive reg
AT
E 
(R
MT
L r
a
tio
)
l
1 2
1.
0
1.
2
1.
4
1.
6
1.
8
2.
0
twin reg
AT
E 
(R
MT
L r
a
tio
)
l
1 2
1.
0
1.
2
1.
4
1.
6
1.
8
2.
0
contrast reg
AT
E 
(R
MT
L r
a
tio
)
33
Figure 7: The marginal ORs in nested subgroups according to the size of conditional OR (thick
solid curve), marginal ORs in nested subgroups maximizing the marginal ORs consecutively
(thick dotted curve), and conditional OR (thin solid curve).
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A Appendix
A.1 The optimality of the estimating equation
Consider all weighted estimating equations in the form of
Snpδ;w, µq
“n´1
nÿ
i“1
rZiwpZiqˆ”t1´ pipZiquRiY p1qi ´ pipZiqp1´RiqY p0qi eδJ rZiı´ µpZiqtRi ´ pipZiqu˙ .
If pipzq “ pi1pzq “ P pR “ 1 | Z “ zq the correct propensity score, the estimating function
converges to
spδ;w, µq “ E
”
wpZqpi1pZqpi0pZqtµ1pZq ´ µ0pZq exppδJ0 Zqu
ı
and δ0 is the root of spδ;w, µq “ 0. Thus, the root of the estimating equation Snpδ;w, µq “ 0,
denoted by pδw,µ, is consistent in estimating δ0, and ?nppδw,µ ´ δ0q converges to a mean zero
Gaussian distribution with a variance-covariance matrix of A´1w,µBw,µA´1w,µ, where
Aw,µ “ E
!
Z˜Z˜JwpZqpi1pZqpi0pZqµ1pZq
)
,
and
Bw,µ “ E
#
Z˜Z˜JwpZq2
ˆ”
pi0pZiqRiY p1qi ´ pi1pZiqp1´RiqY p0qi eδ
J
0
rZiı´ µpZiqtRi ´ pi1pZiqu˙2+ .
First, since
E
ˆ”
pi0pZiqRiY p1qi ´ pipZiqp1´RiqY p0qi eδ
J
0
rZiı | Zi “ z˙ “ 0
and
E
`
Ri ´ pi1pZiq | Zi “ z
˘ “ 0,
Bw,µ ´Bw,µ¯ is semi-positive definite, where
µ¯pzq “
E
ˆ”
pi0pZiqRiY p1qi ´ pi1pZiqp1´RiqY p0qi eδJ0 rZi
ı  
Ri ´ pi1pZiq
( | Zi “ z˙
E
´ 
Ri ´ pi1pZiq
(2 | Zi “ z¯
“pi1pzqpi0pzqµ1pzq
pi1pzqpi0pzq “ µ1pzq.
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Secondly, by Cauchy’s ineqaulity, A´1w,µ1Bw,µ1A
´1
w,µ1 ´A´1w0,µ1Bw0,µ1A´1w0,µ1 is also semi-positive
definite, where
w0pzq “ E
`
pi1pZqpi0pZqµ1pZq | Z “ z
˘
E
ˆ”
pi0pZqRY p1q ´ pi1pZqp1´RqY p0qeδJ0 rZ ´ µ1pZqtR´ pi1pZquı2 | Z “ z˙
“ pi1pzqpi0pzqµ1pzq
E
ˆ“
pi0pzqRpY p1q ´ µ1pzq
‰2 ` ”pi1pzqp1´Rq  Y p0q ´ µ0pzq( eδJ0 rzı2 | Z “ z˙
“ pi1pzqpi0pzqµ1pzq
pi0pzq2pi1pzqvarpY p1q | Z “ zq ` pi0pzqpi1pzq2varpY p0q | Z “ zqe2δJ0 z
“ µ1pzq
pi0pzqµ1pzq ` pi1pzqµ0pzqe2δJ0 z
“ 1
pi0pzq ` pi1pzqeδJ0 z
,
where we used the fact that varpY prq | Z “ zq “ µrpzq. ThereforeA´1w,µBw,µA´1w,µ´A´1w0,µ1Bw0,µ1A´1w0,µ1
is always semi-positive definite, suggesting that an estimating function Snpδ, w0, µ1q with a
limit
E
„ rZw1pδ;Z, pi1q!µ1pZq ´ µ0pZqeδJ rZ) ,
yields the optimal variance among regular estimators of δ0.
A.2 Proof of Theorem 1
Proof. To prove Theorem 1, it is sufficient to verify that the problem and assumptions satisfy
those of Theorem 3.3 in [9], which we repeat here for the reader’s convenience. Let c0 ą 0,
c1 ą 0, a ą 1, v ą 0, s ą 0, and q ą 2 be finite constants, and let tδnuně1, t∆nuně1,
and tτnuně1 be some sequence of positive constants converging to 0. Define the following
assumptions [9, Assumptions 3.3 and 3.4].
Assumption 3. For all n ě 3 and P P Pn, (a) EtmpG; δ0, µ0, pi1qu “ 0, and Ω contains a
ball of radius c1n
´1{2 log n centered at δ0; (b) the map pδ, µ, piq Ñ EtmpG; δ, µ, piqu is twice
continuously Gateaux-differentiable on Ω ˆ T ; (c) for all δ P Ω, 2}EtmpG; δ, µ0, pi1qu} ě
}J0pδ´ δ0q}^ c0, where J0 is the Jacobian matrix of δ ÞÑ ErmpG; δ, µ0, pi1s at δ0; (d) the score
mpg; δ, µ, piq obeys the Neyman orthogonality condition
d
dr
E
“
mpG, δ0, µ0 ` rpsµ´ µ0q, pi1 ` rpspi ´ pi1qq‰ ˇˇˇˇ
r“0
“ 0,
for any psµ, spiq P T .
Assumption 4. Let K be a fixed integer. For all n ě 3 and P P Pn, the following condi-
tions hold: (a) Given a random subset I of t1, . . . , nu of size n{K, the nuisance parameter
estimators ppµ´k0 , ppi´k1 q1ďkďK belong to the realization set Tn with probability 1´∆n, where Tn
contains pµ0, pi1q and is constrained by the conditions below; (b) F1,pµ,piq “ tmjpg; δ, µ, piq | j “
1, ¨ ¨ ¨ , d` 1, δ0 P Ωu is suitably measurable and its uniform covering entropy obeys
sup
Q
logNp}F1,pµ,piq}Q,2,F1,pµ,piq, } ¨ }Q,2q ď v logpa{N q
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for N P p0, 1s, where F1,pµ,piq is a measurable envelope for F1,pµ,piq that satisfies }F1,pµ,piq}P,q ď
c1; (c) rn “ suppµ,piqPTn,δ0PΩ }EtmpG; δ, µ, piqu´EtmpG; δ0, µ0, pi0qu} ď δnτn; (d) r1n log1{2p1{r1nq ď
δn, where
r1n “ suppµ,piqPTn,}δ´δ0}ďτn
ˆ
E
!
}mpG; δ, µ, piq ´mpG; δ0, µ0, pi0q}2
)˙1{2
;
(e) λn ď δnn´1{2, where
λn “ sup
rPp0,1q,pµ,piqPTn,}δ´δ0}ďτn
}B2rE
“
mtG; δ0 ` rpδ ´ δ0q, µ0 ` rpµ´ µ0q, pi1 ` rppi ´ pi1qu
‰ }.
(f) all eigenvalues of the matrix E
”
mpG; δ0, µ0, pi1qmJpG; δ0, µ0, pi1q
ı
are bounded below by a
positive constant.
Theorem 3 ([9, Theorem 3.3]). Suppose that Assumptions 3 and 4 hold. In addition, suppose
that δn ě n´1{2`1{q logpnq and that n´1{2 logpnq ď τn ď δn for all n ě 1 and a constant q ą 2.
Then, the DML2 estimator pδ concentrates in a 1{?n neighborhood of δ0, and are approximately
linear and centered Gaussian:
?
nσ´1
´pδ ´ δ¯ “ 1?
n
nÿ
i“1
ψ¯pGiq `Oppρnq dÑ Np0, Iq,
uniformly over P P Pn, where the size of the remainder term obeys
ρn “ n´1{2`1{q logpnq ` r1n log1{2p1{r1nq ` n1{2λn ` n1{2λ1n,
ψ¯p¨q “ ´σ´1J´10 mp¨, δ0, µ0, pi1q is the influence function, and the approximate variance is
Σ “ J´10 E
”
mpG, δ0, µ0, pi1qmpG, δ0, µ0, pi1qJ
ı
J´J0 .
We proceed by verifying the assumptions of Theorem 3. Let P be a set of measures
satisfying Assumption 1 and T be a measurable subset of the pairs of functions ppi, µq such
that for each Q P P, µ P L2pQq, pi P L8pQq, and pi ď pipzq ď 1´ pi Q-almost everywhere.
We proved Assumption 3(a) in the main text; see equation (8), by using the assumption
in (7): µ1pzq “ µ0pzq exppδJ0 rzq, and thus
ErmpG; δ0, µ0qs “ ErwpZ, δ0qpµ1pZq ´ µ0pZq exppδJ0 rZqqs “ 0.
We will frequently use the fact that for δ P Ω, Z P Z, and pipzq satisfying 0 ă pi ď pipzq ď
1´ pi,
sup
zPZ,δPΩ
texppδJrzqpipzq ` 1´ pipzqu´1 ď C0 (9)
for a constant C0. Applying this with pi “ pi1 by Assumption 1(c), along with Assumption 1(e)
ensures that BErmpG; δ, µ0, pi1q | Z “ zs{Bδ and the second derivative have an integrable
envelope function, and therefore E
“
mpG; δ, µ0, pi1q
‰
is differentiable with respect to δ with
Jacobian
J0pδq “ E
¨˚
˚˝ rZ rZJ eδJ rZipi1pZqpi0pZqteδJ0 rZpi1pZq ` pi0pZquµ0pZq”
eδJ rZpi1pZq ` pi0pZqı2
‹˛‹‚,
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which is continuous in δ and positive definite with its smallest eigenvalue uniformly bounded
away from zero for δ P Ω. We can choose a small open ball centered at δ0, N , such that for any
δ P N , |J0pδq ´ J0pδ0q|ij ă , for all components 1 ď i, j ď d` 1, where  is a small constant
to be specified later. By the Intermediate Value Theorem, for any δ P N , there exists δ¯ P N
such that
}EtmpG; δ, µ0, pi1qu} “ }J0pδ¯qpδ ´ δ0q}
ě}J0pδ0qpδ ´ δ0q} ´ }tJ0pδ¯q ´ J0pδ0qupδ ´ δ0q}
ě}J0pδ0qpδ ´ δ0q} ´ pd` 1q}δ ´ δ0}
ě}J0pδ0qpδ ´ δ0q} ´ }J0pδ0qpδ ´ δ0q}{2,
if  ď λ0{2pd` 1q, where λ0 is the smallest eigenvalue of
J0 “ J0pδ0q “ E
¨˚
˝ rZ rZJ eδJ0 rZipi1pZqpi0pZqµ0pZq”
eδ
J
0
rZpi1pZq ` pi0pZqı ‹˛‚.
Therefore,
2}EtmpG; δ, µ0, pi1qu} ě }J0pδ ´ δ0q},
for any δ within the ball. For δ outside N , let
c0 “ inf
δPΩ´N }EtmpG; δ, µ0, pi1qu}.
c0 ą 0 due to the uniform continuity of EtmpG; δ, µ0, pi1qu in the compact set Ω ´ N . This
verifies Assumption 3(c).
To verify the Gateaux-differentiability of m, note that for δ P Ω, pµ, piq P T , pµ` rdµ, piq P
T , and pµ, pi ` rdpiq P T ,
1
r
“
EtmpG; δ, µ` rdµ, piqu ´ EtmpG; δ, µ, piqu
‰
“´ E
$&%
 
pi1pZqp1´ pipZqq ´ pi0pZqpipZq
(
eδ
J rZ
eδJ rZpipZq ` 1´ pipZq dµpZq
,.- ,
and
1
r
“
EtmpG; δ, µ, pi ` rdpiqu ´ EtmpG; δ, µ, piqu
‰
“´ E
$’&’%
”
pi1pZqtµ1pZq ´ µpZqeδJ rZu ` pi0pZqtµ0pZq ´ µpZquı eδJ rZ´
eδJ rZpipZq ` 1´ pipZq¯´eδJ rZtpipZq ` rdpipZqu ` 1´ pipZq ´ rdpipZq¯dpipZq
,/./- .
By Dominated Convergence Theorem, we may exchange the limrÑ0 with the expectation
due to the presence of integrable envelop functions (using Assumption 1). Therefore, the
Gateuaux derivative with respect to µ along the direction of dµ exists and is
´E
$&%
“
pi1pZqt1´ pipZqu ´ pi0pZqpipZq
‰
eδ
J rZdµpZq
eδJ rZpipZq ` 1´ pipZq
,.- .
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The Gateuaux derivative with respect to pi along the direction of dpi also exists and is
´E
$’’&’’%
”
pi1pZqtµ1pZq ´ µpZqeδJ rZu ` pi0pZqtµ0pZq ´ µpZquı eδJ rZ!
eδJ rZpipZq ` 1´ pipZq)2 dpipZq
,//.//- .
The smoothness of the numerator, and boundedness of the denominator similarly allow for
second order differentiability.
To examine the orthogonality condition, i.e., Assumption 3(d), let psµ, spiq P T , dµpzq “sµpzq ´ µ0pzq, dpipzq “ spipzq ´ pi1pzq, and
m¯pµ, pi, fq “ E
»–Z #p1´ pipZqqRpY ´ µpZqefpZqq
efpZqpipZq ` 1´ pipZq ´
pipZqp1´RqpY ´ µpZqqefpZq
efpZqpipZq ` 1´ pipZq
+fifl .
Then, for
g0prq “m¯pµ0 ` rdµ, pi1 ` rdpi, f0q
“E
˜
Z
ppi0pZq ´ rdpipZqqRpY1 ´ pµ0pZq ` rdµpZqqef0pZqq
ef0pZqppi1pZq ` rdpipZqq ` 1´ pi1pZq ´ rdpipZq
¸
´ E
˜
Z
ppi1pZq ` rdpipZqqp1´RqpY0 ´ pµ0pZq ` rdµpZqqqef0pZq
ef0pZqppi1pZq ` rdpipZqq ` 1´ pi1pZq ´ rdpipZq
¸
“E
˜
Z
r2ef0pZqdpipZqdµpZq
ef0pZqtpi1pZq ` rdpipZqu ` pi0pZq ´ rdpipZq
¸
,
where f0pzq “ δJ0 z. Let µ¯pzq “ µ0pzq ` dµpzq and p¯ipzq “ pi1pzq ` dpipzq. Using a similar
argument as above, because (9) is bounded for pi “ pi1 by Assumption 1(c) and µ1pzq is
integrable by Assumption 1(e), the Dominated Convergence Theorem yields
dg0prq
dr
“2rE
˜
Z
ef0pZqdpipZqdµpZq
ef0pZqppi1pZq ` rdpipZqq ` 1´ pi1pZq ´ rdpipZq
¸
´ r2E
˜
Z
ef0pZqpef0pZq ´ 1qdpipZq2dµpZq
tef0pZqppi1pZq ` rdpipZqq ` 1´ pi1pZq ´ rdpipZqu2
¸
Therefore
dg0prq
dr
ˇˇˇˇ
r“0
“ 0,
which verifies Assumption 3(d).
Assumption 2 implies that there exists sequences logpnqn´1{4 ď an “ op1q, and ∆1n “ op1q,
such that
}ppip¨q ´ pi1p¨q}P,2 ` }pµp¨q ´ µ0p¨q}P,2 ď ann´1{4,
with probability 1 ´∆1n{2. Note that an can be chosen such that these hold when ppi and pµ
are estimated using only p1´K´1qn (as opposed to n) samples. Let
Tn “
!
ppi, µq | pi, µ are measureable, pip¨q P rpi, 1´ pis, µp¨q P rµ, ´1µ s,
and }pip¨q ´ pi1p¨q}P,2 ` }µp¨q ´ µ0p¨q}P,2 ď ann´1{4
)
,
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Then, P ptpppip´kq, pµp´kqq P TnuKk“1q ě 1 ´ K∆1n. Let ∆n “ K∆1n, and Assumption 4(a) is
satisfied.
For Q P P, and pµ, piq P T ,
}mpG; sδ, pi, µq ´mpG; δ0, pi, µq}Q,2
“
›››››› rZ
´
pip1´RqY p0q ` µpR´ piq
¯˜ exppsδJ rZq
esδJ rZpi ` p1´ piq ´
exppδJ0 rZq
eδ
J
0
rZpi ` p1´ piq
¸››››››
Q,2
ď
››› rZ  pipi0µ0 ` µppi1 ´ piq(›››
Q,2
›››››p1´ piq exppsδJ0 rZq ´ exppδJ rZqpesδJ rZpi ` p1´ piqqpeδJ0 rZpi ` p1´ piqq
›››››
Q,2
ďC
›››exppsδJ0 rzq ´ exppδJrzq›››8
ďCLrad}sδ ´ δ0}8,
where we suppressed Z in functions such as pipZq, µpZq, etc to simplify notation, Lrad is
the Lipschitz constant of t ÞÑ expptq over |t| ď supδPΩ,zPZ |δJrz|. Therefore, mpG; δ, µ, piq is
Lipschitz in δ. For all pµ, piq P T , (9) and the fact that µ P L2pQq imply that there exists a
squared-integrable envelope function F1,pµ,piq. This, the Lipschitz constraint, and the bound
logNpN ,Ω, }¨}8q ď rv logpra{N q on the parameter space imply that supQ logNpN}F1,pµ,piq}Q,2,F1,µ,pi, }¨
}Q,2q ď v logpa{N q. Thus Assumption 4(b) is verified.
rn “}EtmpG; δ, µ, piqu ´ EtmpG; δ, µ0, pi1qu}
“
››››››››E
»—–rZ ppi1 ´ piq exppδJ rZqppi1pµ1 ´ µ exppδJ rZqq ` p1´ piqpµ0 ´ µqq´
eδJ rZpi ` p1´ piq¯´eδJ rZpi1 ` p1´ pi1q¯
fiffifl
››››››››
ď rC1}pi ´ pi1}P,2,
for a finite constant rC1. Therefore, by Assumption 4(c), we can choose τn “ pa3{8n n´1{4q and
δn “ ?an to satisfy rn ď rC1}pi ´ pi1}P,2 ď δnτn for adequately large n, using the definition of
Tn.
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Next,!
E}mpG; δ, µ, piq ´mpG; δ0, µ0, pi1q}2
)1{2
ď?3
!
E}mpG; δ, µ, piq ´mpG; δ, µ0, piq}2
)1{2
`?3
!
E}mpG; δ, µ0, piq ´mpG; δ, µ0, pi1q}2
)1{2
`?3
!
E}mpG; δ, µ0, pi1q ´mpG; δ0, µ0, pi1q}2
)1{2
“?3
¨˚
˚˝˚
E
»——–} rZ}2 expp2δJ rZq
 
pi1p1´ piq2 ` pi0pi2
(´
eδJ rZpi ` p1´ piq¯2 pµ´ µ0q2
fiffiffifl‹˛‹‹‚
1{2
`?3
¨˚
˚˝˚˚
E
»———–} rZ}2
expp2δJ rZq"pi1 ´Y p1q ´ µ0 exppδJ rZq¯2 ` pi0 ´Y p0q ´ µ0¯2*´
eδJ rZpi ` p1´ piq¯2 ´eδJ rZpi1 ` pi0¯2 ppi1 ´ piq2
fiffiffiffifl
‹˛‹‹‹‚
1{2
`?3
¨˚
˚˝˚˚
E
»———–} rZ}2
pi21pi
2
0
"
pi1
´
Y p1q ´ µ1
¯2 ` pi0 ´Y p0q ´ µ0¯2 ` ppi1µ1 ` pi0µ0q2{pi1*´
eδJ rZpi ` p1´ piq¯2 ´eδJ rZpi1 ` pi0¯2 peδ
J rZ ´ eδJ0 rZq2
fiffiffiffifl
‹˛‹‹‹‚
1{2
ď rC2 `}pi ´ pi1}P,2 ` }µ´ µ0}P,2 ` }δ ´ δ0}2˘
where pµ, piq P Tn, }δ ´ δ0}2 ď τn, rC2 is a finite constant that depends on constants such as
σ2U , pi, µ in Assumption 1. Therefore,
r1n “ suppµ,piqPTn,}δ´δ0}2ďτn
!
E}mpG; δ, µ, piq ´mpG; δ0, µ0, pi1q}2
)1{2 ď rC2 ´ann´1{4 ` τn¯ ,
Thus, r1n log1{2p1{r1nq ď rC2a3{8n n´1{4alogpnq ď δn and, thus, Assumption 4(d) is satisfied.
Let df pzq “ sfpzq ´ f0pzq “ psδ ´ δ0qJrz. Define
kprq “m¯pµ0 ` rdµ, pi1 ` rdpi, f ` rdf q
“E
¨˚
˝Z
”
ppi0 ´ rdpiqRpY1 ´ pµ0 ` rdµqef0`rdf q ´ ppi1 ` rdpiqp1´RqpY0 ´ pµ0 ` rdµqqef0`rdf
ı
ef0`rdf ppi1 ` rdpiq ` pi0 ´ rdpi
‹˛‚
“E
¨˚
˝Zef0
”
p1´ erdf qpi0pi1µ0 ´ rp1´ erdf qpi1µ0dpi ` r2erdfdµdpi
ı
ef0`rdf ppi1 ` rdpiq ` pi0 ´ rdpi
‹˛‚
“E
"
Zef0pZqh1pZ, rq
h2pZ, rq
*
,
where h1pz, rq “ p1´erdf pzqqpi0pzqpi1pzqµ0pzq´rp1´erdf pzqqpi1pzqµ0pzqdpipzq`r2erdf pzqdµpzqdpipzq,
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and h2pz, rq “ ef0pzq`rdf pzqtpi1pzq ` rdpipzqu ` pi0pzq ´ rdpipzq. Similar as above, by the Domi-
nated Convergence Theorem, we have
d2kprq
dr2
“E
¨˝
Zef0pZq
«
B2h1pZ, rq{Br2
h2pZ, rq ´ 2
Bh1pZ, rq{BrBh2pZ, rq{Br
h22pZ, rq
´ h1pZ, rqB
2h2pZ, rq{Br2
h22pZ, rq
` 2h1pZ, rqtBh2pZ, rq{Bru
2
h32pZ, rq
ff‚˛,
where
Bh1pz, rq
Br “´ e
rdfpi0pi1µ0df ´ p1´ erdf qpi1µ0dpi `R11pr, z;κq
B2h1pz, rq
Br2 “´ e
rdfpi0pi1µ0d
2
f `R12pr, z;κq
Bh2prq
Br “pe
f0`rdf ´ 1qdpi ` ef0`rdfpi1df `R21pr, z;κq
B2h1prq
Br2 “e
f0`rdfpi1d2f `R22pr, z;κq,
κ “ pdpi, dµ, df qJ, and Rijpr, z;κq is a function of r, z satisfying that
sup
pr,zqPr0,1sˆZ
|Rijpr, z;κq|
|dpipzqdµpzq| ` |df pzqdpipzq| ď
rC3
for a constant rC3. Therefore, after careful regrouping,
λn “ sup
rPp0,1q,pµ¯,p¯iqPTn,|δ¯´δ0|ďτn
›››››d2kprqdr2
›››››
ď rC4p}df }2P,2 ` }df }P,2}dpi}P,2 ` }dpi}P,2}dµ}P,2 ` }dpi}2P,2q,
ďC˜5pτ2n ` τnann´1{4 ` a2nn´1{2q ď
?
ann
´1{2 “ δnn´1{2
where rCi are finite constants. Thus, Assumption 4(d) is verified.
Lastly, to verify Assumption 4(e), note that
E
”
mpG; δ0, µ0, pi1qmJpG; δ0, µ0, pi1q
ı
“E
$’’&’’%rZ rZJpi0pZqpi1pZq
pi0pZqvarpY p1q | Zq ` pi1pZqvarpY p0q | Zqe2δJ0 rZ!
eδ
J
0
rZpi1pZq ` pi0pZq)2
,//.//- ,
which is non-degenerate, because Assumption 1 ensures that varpY prq | Z “ zq ě σL ą 0.
Note that our choice of δn and τn satisfies logpnq{?n ď a3{8n n´1{4 “ τn ď ?an “ δn, and
δn “ ?an ě logpnq´1{2 ě n´1{2`1{q logpnq for any constant q ą 2. Therefore, all assumptions
of Theorem 3 are verified. Applying this theorem completes the proof.
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Proof of Theorem 2: First, for c ą 0, we show that ADpcq ě c, by showing that
EpY p1q | DpZq ě cq ě cEpY p0q | DpZq ě cq. This follows from the following application of the
tower property of conditional expectations,
EpY p1q | DpZq ě cq “ EtEpY p1q | Zq | DpZq ě cu
“ EtDpZqEpY p0q | Zq | DpZq ě cu
ě EtcEpY p0q | Zq | DpZq ě cu
“ cEtEpY p0q | Zq | DpZq ě cu
“ cEtY p0q | DpZq ě cu.
Now, let 0 ă c1 ă c. Expanding ADpc1q gives
ADpc1q “ EtY
p1q | DpZq ě c1u
EtY p0q | DpZq ě c1u
“ EtY
p1q | DpZq ě cup` EtY p1q | DpZq P rc1, cqup1´ pq
ErY p0q | DpZq ě cup` EtY p0q | DpZq P rc1, cqup1´ pq ,
where p “ P tDpZq ě c | DpZq ě c1u. Now, consider the expression in the numerator, which
we expand and bound as
EtY p1q | DpZq ě cup` EtY p1q | DpZq P rc1, cqup1´ pq
“ ADpcqEtY p0q | DpZq ě cup` EtY p1q | DpZq P rc1, cqup1´ pq
“ ADpcqEtY p0q | DpZq ě cup` EtDpZqEpY p0q | Zq | DpZq P rc1, cqup1´ pq
ď ADpcqEtY p0q | DpZq ě cup` cEtY p0q | DpZq P rc1, cqup1´ pq
ď ADpcq
”
EtY p0q | DpZq ě cup` EtY p0q | DpZq P rc1, cqup1´ pq
ı
,
where in the last inequality we used the fact that ADpcq ě c. Plugging this into the expression
for ADpc1q gives
ADpc1q ď ADpcqpEtY
p0q | DpZq ě cup` EtY p0q | DpZq P rc1, cqup1´ pqq
EtY p0q | DpZq ě cup` EtY p0q | DpZq P rc1, cqup1´ pq “ ADpcq.
A.3 Examples of CATE vs ATE measured by OR and HR
OR example:
Consider the case where the response rate of a binary outcome in the control arm is
pi “
#
1´ in`1 if i is even,
i
n`1 if i is odd,
the response rate in the treatment arm is piθi{p1 ´ pi ` piθiq, logpθiq “ logp2q ´ logp4qpi ´
1q{pn ´ 1q, and n “ 100. Thus, these 100 patients are sorted according to their conditional
OR, which is monotone decreasing from 2 to -2. The marginal OR in 10 patients with the
highest conditional OR is only 1.14, though the conditional OR of each patient is above 1.76.
On the other hand, we can select a different subgroup of 10 patients, in which the marginal
OR is as high as 1.66. Figure 7 plots the marginal ORs in a sequence of subgroups based
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on (1) the optimal grouping maximizing the marginal ORs and (2) the grouping according to
the conditional OR of each patient. The former can be substantially higher than the latter.
HR example:
Consider the following example, where λ1pt|zq{λ0pt|zq is constant, i.e., there is no treatment
effect heterogeneity, but exptpβ1 ´ β0qJzu depends on z. Let
λ0pt | Zq “ 2tZ´1Ipt ă 1q ` Z´2Ip1 ď t ă 2q ` Z´3Ipt ě 2qu,
λ1pt | Zq “ 0.5λ0pt | Zq, and Z „ Up0, 2q, where Ip¨q is the indicator function. Solving the
score equations from the mis-specified Cox model results in pβ1, β0q « p´1.85,´1.55q in the
absence of any censoring, implying nontrivial treatment effect heterogeneity.
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